Insider Trading History of Wittouck Amaury

The following table details the insider trading activities (stock purchases, stock sales, and stock option exercises) of Wittouck Amaury since 2024. This trader's CIK number is 1841311. At the time of last reporting, Wittouck Amaury was the Officer of Lexicon Pharmaceuticals, Inc.. (stock ticker symbol LXRX). Also see all insider trading activities at Lexicon Pharmaceuticals, Inc..

Note that in the past Wittouck Amaury also reported insider trading activities as an insider of the following companies:

Yearly summary of insider trading at Lexicon Pharmaceuticals, Inc. (LXRX) by Wittouck Amaury

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2026 LXRX 0 $0 0 $0 20,421,735 $0

Yearly summary of insider trading at Cava Group, Inc. (CAVA) by Wittouck Amaury

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2024 CAVA 0 $0 22,500,000 $2,353,050,000 0 $0


Insider trading activities at 2 companies by Wittouck Amaury:

1. Lexicon Pharmaceuticals, Inc. (LXRX)

2. Cava Group, Inc. (CAVA)

Table 1. Insider trading of Lexicon Pharmaceuticals, Inc. (LXRX) by Wittouck Amaury

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2026-04-30 LXRX Option Ex 20,421,735 .00 0

Table 2. Insider trading of Cava Group, Inc. (CAVA) by Wittouck Amaury

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2024-11-18 CAVA Sale 8,000,000 134.13 1,073,040,000
2024-08-26 CAVA Sale 6,000,000 116.36 698,160,000
2024-06-05 CAVA Sale 3,000,000 87.25 261,750,000
2024-03-21 CAVA Sale 2,000,000 66.25 132,500,000
2024-02-27 CAVA Sale 3,500,000 53.60 187,600,000

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Wittouck Amaury (Officer of Lexicon Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.